PMID- 26940162
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20180628
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 165
DP  - 2016 May
TI  - Potential Predictors of Poor Visual Outcome in Human Leukocyte 
      Antigen-B27-Associated Uveitis.
PG  - 179-87
LID - S0002-9394(16)30074-5 [pii]
LID - 10.1016/j.ajo.2016.02.024 [doi]
AB  - PURPOSE: To identify potential predictors of permanent vision loss in patients 
      with human leukocyte antigen (HLA)-B27-associated uveitis in a tertiary referral 
      center. DESIGN: Retrospective case-control study. METHODS: The charts of 212 
      patients (338 eyes) with HLA-B27-associated uveitis that visited the University 
      Medical Center Utrecht with a follow-up of at least 6 months were retrospectively 
      studied. Clinical features at presentation and during follow-up were compared to 
      final visual outcome in quiescent state. Eyes with (sub-) normal vision (>20/50) 
      were compared with visually impaired (</=20/50) and blind (</=5/50, or a visual field 
      of <10 degrees) eyes, using survival analysis. A multivariate Cox proportional 
      hazards analysis was performed to analyze potential predictors for permanent 
      vision loss. RESULTS: Median follow-up was 10.4 years (range, 0.5-44.7 years). 
      During follow-up 226 eyes (66%) experienced vision loss up to 20/50, but most 
      recovered. Twenty patients (9%) became permanently visually impaired or blind in 
      at least 1 eye because of uveitis, after a median of 9.7 years (range, 0-20.9 
      years). The main cause was secondary glaucoma or related to glaucoma surgery 
      (12/22 eyes, 55%). Survival analysis showed, after adjustment for age and sex, an 
      ocular pressure of >21 mm Hg, hypotony, and panuveitis to be potential predictors 
      at presentation, and the development of secondary glaucoma or hypotony to be 
      predictors of blindness or visual impairment during follow-up. CONCLUSIONS: The 
      long-term visual prognosis of HLA-B27-associated uveitis is relatively good, but 
      the true incidence of permanent vision loss is probably still underestimated. Our 
      findings highlight the importance of proper control of intraocular pressure.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Verhagen, Fleurieke H
AU  - Verhagen FH
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands; Laboratory of Translational Immunology, University Medical Center 
      Utrecht, Utrecht, Netherlands. Electronic address: F.H.Verhagen@umcutrecht.nl.
FAU - Brouwer, Anna H
AU  - Brouwer AH
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands.
FAU - Kuiper, Jonas J W
AU  - Kuiper JJ
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands; Laboratory of Translational Immunology, University Medical Center 
      Utrecht, Utrecht, Netherlands.
FAU - Ossewaarde-van Norel, Jeannette
AU  - Ossewaarde-van Norel J
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands.
FAU - Ten Dam-van Loon, Ninette H
AU  - Ten Dam-van Loon NH
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands.
FAU - de Boer, Joke H
AU  - de Boer JH
AD  - Department of Ophthalmology, University Medical Center Utrecht, Utrecht, 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20160303
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (HLA-B27 Antigen)
SB  - IM
MH  - Adult
MH  - Blindness/*diagnosis/immunology
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Glaucoma/diagnosis
MH  - HLA-B27 Antigen/*immunology
MH  - Humans
MH  - Intraocular Pressure
MH  - Male
MH  - Ocular Hypertension/diagnosis
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Uveitis/*diagnosis/immunology
MH  - Vision, Low/*diagnosis/immunology
MH  - Visual Acuity
EDAT- 2016/03/05 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/03/05 06:00
PHST- 2015/10/07 00:00 [received]
PHST- 2016/02/19 00:00 [revised]
PHST- 2016/02/19 00:00 [accepted]
PHST- 2016/03/05 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - S0002-9394(16)30074-5 [pii]
AID - 10.1016/j.ajo.2016.02.024 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2016 May;165:179-87. doi: 10.1016/j.ajo.2016.02.024. Epub 2016 
      Mar 3.